Total Funding
51
82
Total FundingPost-IPO Equity raised
Growth Score
-16 pts
Heat Score
21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
28983
MacroGenics is a biotechnology company developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases.
- Eric Risser: President and Chief Executive OfficerPast Role: MacroGenics, Chief Business Officer & SVP BD & Portfolio Management
- Heather Preston: Observer of BoardsPast Role: TPG Biotech, Partner and Managing Director
About the Company
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.
The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's
Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology.
The company was founded in 2000 and is headquartered in Rockville, Maryland.
